[Translation] A randomized, open-label, single-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of piribedil sustained-release tablets (50 mg) in healthy Chinese subjects after meal administration

主要研究目的：按有关生物等效性试验的规定，选择Les Laboratoires Servier为持证商的吡贝地尔缓释片（商品名：泰舒达，规格：50mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂吡贝地尔缓释片（规格：50mg）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂吡贝地尔缓释片（规格：50mg）和参比制剂吡贝地尔缓释片（商品名：泰舒达，规格：50mg）的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, Piribedil sustained-release tablets (trade name: Taishuda, specification: 50mg) with Les Laboratoires Servier as the licensee were selected as the reference preparation, and the test preparation Piribedil sustained-release tablets (specification: 50mg) produced and provided by Shijiazhuang Siyao Co., Ltd. were subjected to human bioequivalence test after meal administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary research purpose: To observe the safety of oral administration of the test preparation Piribedil sustained-release tablets (specification: 50mg) and the reference preparation Piribedil sustained-release tablets (trade name: Taishuda, specification: 50mg) in healthy subjects.

Start Date06 Dec 2024

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20243357

/ CompletedNot Applicable

尼莫地平片（30mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of nimodipine tablets (30 mg) in Chinese healthy subjects under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择拜耳医药保健有限公司为持证商的尼莫地平片（商品名：尼膜同，规格：30mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂尼莫地平片（规格：30mg）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂尼莫地平片（规格：30mg）和参比制剂尼莫地平片（商品名：尼膜同，规格：30mg）的安全性。

[Translation]

The main purpose of the study: According to the relevant provisions of the bioequivalence test, nimodipine tablets (trade name: Nimotong, specification: 30mg) of which Bayer HealthCare Co., Ltd. is the licensee was selected as the reference preparation, and the human bioequivalence test of the test preparation nimodipine tablets (specification: 30mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was conducted on the fasting administration, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation nimodipine tablets (specification: 30mg) and the reference preparation nimodipine tablets (trade name: Nimotong, specification: 30mg) by healthy subjects.

Start Date12 Oct 2024

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20243354

/ CompletedNot Applicable

尼莫地平片（30mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择拜耳医药保健有限公司为持证商的尼莫地平片（商品名：尼膜同，规格：30mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂尼莫地平片（规格：30mg）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂尼莫地平片（规格：30mg）和参比制剂尼莫地平片（商品名：尼膜同，规格：30mg）的安全性。

[Translation]

The main purpose of the study: According to the relevant provisions of the bioequivalence test, nimodipine tablets (trade name: Nimotong, specification: 30mg) of which Bayer HealthCare Co., Ltd. is the licensee was selected as the reference preparation, and the human bioequivalence test of the test preparation nimodipine tablets (specification: 30mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was conducted to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary purpose of the study: To observe the safety of oral administration of the test preparation nimodipine tablets (specification: 30mg) and the reference preparation nimodipine tablets (trade name: Nimotong, specification: 30mg) by healthy subjects.

Start Date05 Oct 2024

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

100 Clinical Results associated with SSY Group Ltd.

0 Patents (Medical) associated with SSY Group Ltd.

Literatures (Medical) associated with SSY Group Ltd.

01 Feb 2025·Current Cancer Drug Targets

Gamma-tocotrienol Inhibits Proliferation and Growth of HSD17B4 Overexpressing HepG2 Liver Cancer Cells

Article

Author: Wang, Yaqi ; Hou, Lianguo ; Yao, Min ; Zhang, Nan ; Liang, Xijia ; Hu, Meng ; Wang, Xiaoming ; Shi, Yun ; Jiang, Lingling

Introduction:Hydroxysteroid 17-beta dehydrogenase 4 (HSD17B4) is involved in the progression of hepatocellular carcinoma (HCC).Aims:This study aimed to investigate the inhibitory effect of gamma-tocotrienol (γ-T3) on the proliferation and growth of HSD17B4-overexpressing HepG2 cells.Methods:HepG2 cells were transfected with empty or HSD17B4-overexpressing plasmids, followed by vitamin E (VE) or γ-T3 treatment. MTS assay, Western blotting, qRT-PCR, and flow cytometry were employed to assess cell proliferation, protein expression, mRNA levels, and apoptosis. HSD17B4 interaction with γ-T3 was assessed by quantifying γ-T3 in the collected precipitate of HSD17B4 using anti-flag magnetic beads. Tumor xenografts were established in NSG mice, and tumor growth was monitored.Results:HSD17B4 overexpression significantly promoted HepG2 cell proliferation, which was effectively counteracted by VE or γ-T3 treatment in a dose-dependent manner. VE and γ-T3 did not exert their effects through direct regulation of HSD17B4 expression. Instead, γ-T3 was found to interact with HSD17B4, inhibiting its activity in catalyzing the conversion of estradiol (E2) into estrone. Moreover, γ-T3 treatment led to a reduction in cyclin D1 expression and suppressed key proliferation signaling pathways, such as ERK, MEK, AKT, and STAT3. Additionally, γ-T3 promoted apoptosis in HSD17B4-overexpressing HepG2 cells. In an in vivo model, γ-T3 effectively reduced the growth of HepG2 xenograft tumors.Conclusion:In conclusion, our study demonstrates that γ-T3 exhibits potent anti-proliferative and anti-tumor effects against HepG2 cells overexpressing HSD17B4. These findings highlight the therapeutic potential of γ-T3 in HCC treatment and suggest its role in targeting HSD17B4-associated pathways to inhibit tumor growth and enhance apoptosis.

01 Apr 2024·International Immunopharmacology

Irbesartan ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing NLRP3 inflammasomes in vivo and in vitro

Article

Author: Gao, Menghan ; Guo, Weiying ; Zhao, Meng ; Long, Weihong ; Li, Yuan ; Yu, Lu ; Zhang, Haifeng

OBJECTIVESDiabetic nephropathy (DN) is characterized by albuminuria and renal dysfunction caused by diabetes. At present there is no specific treatment for DN. Irbesartan (IRB) is an angiotensin receptor inhibitor indicated for the treatment of hypertension and DN. However, the underlying molecular mechanisms of IRB on DN remains obscure.METHODSRAW264.7 macrophages were incubated in RPMI-1640, cell viability was evaluated by CCK-8 assays, transcriptional level of proinflammatory cytokines and was measured by ELISA and qPCR, NLRP3 inflammasome and Nrf2/Keap1 related proteins were measured by Western blotting and immunohistochemistry. Streptozotocin (STZ)-induced diabetic male C57BL/6 mice were used to evaluate the therapeutic effect of IRB on DN. Key findings First, we found that IRB improved high glucose-induced cell inflammation by inhibiting the transcription of IL-1β and IL-18. IRB activated the Nrf2/Keap1 pathway and decreased the release of reactive oxygen species (ROS). IRB also suppressed the expression of NLRP3 and caspase-1. IRB combined with the N-acetylcysteine (NAC) significantly inhibited the activation of NLRP3 inflammasomes. Conversely, IRB combined with the Nrf2-related inhibitor ML385 enhanced NLRP3 inflammasome activation, suggesting that IRB suppressed NLRP3 inflammasome via the Nrf2 pathway. In vivo study, HE staining and immunohistochemistry analysis further showed that IRB ameliorated high glucose-induced renal injury by elevating the expression of the Nrf2/Keap1 signaling pathway and suppressing the proinflammatory cytokine and NLRP3 inflammasome activation.CONCLUSIONSOur results suggested that IRB ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing the NLRP3 inflammasomes in vivo and in vitro. These findings provide new therapeutic strategies of diabetic nephropathy.

01 Jan 2024·Clinical Pharmacology in Drug Development

Bioequivalence of Blonanserin Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects

Article

Author: Chen, Lulu ; Wang, Jie ; Li, Xiaohui ; Xia, Man ; Huang, Lifeng ; Lei, Yuyan ; Li, Chao ; Li, Canxia ; Chen, Weiming ; Liu, Wanying ; Wang, Caihong ; Yan, Yu ; Lu, Junli

AbstractBlonanserin is a novel oral antischizophrenic drug. Under fasting (n = 50) and fed (n = 60) conditions, this study compared the bioequivalence of the generic blonanserin tablet with the reference blonanserin tablet. In this single‐center, randomized, open‐label, 2‐period, 2‐sequence, crossover study, 110 patients were randomly given a 4‐mg dose of either the test or reference blonanserin tablet with a 14‐day washout period. Blood samples were taken before performing and up to 72 hours following. A validated high‐performance liquid chromatography‐tandem mass spectrometry technique was used to measure the levels of blonanserin in plasma. Safety was evaluated throughout the study. The study found no significant differences in the maximum observed drug concentration in the plasma (Cmax), the area under the plasma concentration‐time curve from time 0 to the last sampling time (AUC0‐t), and the area under the plasma concentration‐time curve from time 0 to infinity (AUC0‐∞) between the 2 blonanserin formulations. The 90% confidence intervals of the geometric mean ratio of the test/reference formulations for Cmax, AUC0‐t, and AUC0‐∞ were within the 80%‐125% limit. Food dramatically raised blonanserin exposure, and also significantly prolonged the lag time of absorption. No serious adverse events occurred. These results indicate that the 2 blonanserin formulations were bioequivalent and well tolerated in healthy Chinese subjects. In clinical treatment, it is necessary to consider the food effect of blonanserin.

News (Medical) associated with SSY Group Ltd.

23 Jun 2022

·www.prnewswire.com

Intravenous Fluid Bags Market Size, Share & Industry Analysis, By End-user and Regional Forecast, 2020-2024

NEW YORK, June 23, 2022 /PRNewswire/ -- The Intravenous Fluid Bags Market offers a comprehensive analysis on new product launches, the latest trends, and the post-pandemic impact on businesses. The market is segmented by End-User (hospitals, home healthcare, and others). The intravenous fluid bags market share growth by the hospital segment will be significant during the forecast period. Intravenous fluid bags are used in hospitals, including both multispecialty hospitals and general government hospitals, to provide intravenous solutions to prevent dehydration, maintain blood pressure, and provide medicines or nutrients to patients. Such factors will increase the demand for the market in focus during the forecast period. Moreover, the market value is set to grow by USD 667.51 million, progressing at a CAGR of 5.67% from 2019 to 2024, as per the latest report by Technavio. Technavio has announced its latest market research report titled Intravenous Fluid Bags Market by End-user and Geography - Forecast and Analysis 2020-2024 Look out for more information on market dynamics scenario, demand & supply forces, product offerings, financial information, and SWOT analysis. All at affordable Plans Market Segmentation The Intravenous Fluid Bags Market is segmented by geography (North America, Europe, APAC, and South America). 36% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for intravenous fluid bags market in North America. Market growth in this region will be faster than the growth of the market in South America. The rising prevalence of chronic diseases will facilitate the intravenous fluid bags market growth in North America over the forecast period. Company Profiles The report analyzes the market's competitive landscape and offers information on several market vendors, including: Amcor Ltd. B. Braun Melsungen AG Baxter International Inc. Fresenius Kabi AG ICU Medical Inc. JW Lifescience Corp. Merit Medical Systems Inc. PolyCine GmbH Sippex - A MEDIPPEX Co. Smiths Medical Group Ltd. The intravenous fluid bags market is fragmented and the vendors are deploying growth strategies such as focusing on product innovation and increasing the existing product capabilities to compete in the market. More insights on the market share of various regions with latest vendor news & product offerings. Request for Details Market Dynamics Rising Prevalence of Chronic Diseases to Drive the Market Growth: The Centers for Disease Control and Prevention (CDC) reported that around 795,000 people in the US suffer from a stroke every year. About 87% of these people get ischemic strokes, which leads to blockage of the arteries leading to the brain. In such cases, surgeries such as embolectomy, angioplasty, and surgical arteriovenous malformation repair are performed to remove the blood clot. Chronic conditions such as diabetes are increasing the prevalence of diabetic retinopathy, which can damage the blood vessels of the retina, leading to blindness. Moreover, the rising prevalence of diabetes in the US will increase the number of diabetic retinopathy cases, which will increase the demand for intravenous fluid bags in the market. Similarly, the number of surgeries for breast and ovarian cancer has increased in Australia, driving the demand for intravenous fluid bags in the country. Essentially, the increasing prevalence of chronic diseases is driving the global intravenous fluid bags market growth during the forecast period. Technological Innovations will be a Key Trend of the Market in the Near Future: Vendors that offer intravenous fluid bags are focused on improving the features of their products. They have developed specialized intravenous blood fluid bags that can withstand low temperatures and offer a high level of safety. For instance, the Reusable Pressure Infusion Bag by Pacific Hospital Supply is a reusable latex-free polyurethane (PU) bag that is used for the infusion of blood, blood plasma, and other liquids. Similarly, in April 2019, Amcor Plc. launched a recyclable, high-barrier flexible packaging, AmLite Ultra Recyclable, for packaging pharmaceutical products. Companies also use this high-barrier flexible packaging product to pack up a range of food, home care, and personal care products. Moreover, the vendors have also developed customized intravenous fluid bags to provide personalized therapeutic solutions. For instance, Technoflex provides 2-CHAMBER BAGS made of DEHP-free or PP material. They are used to provide customized solutions to various applications such as parenteral nutrition and drug reconstruction. Such innovations in intravenous fluid bags drive the global intravenous fluid bags market growth. This Market Report gives insights on the latest drivers, trends, and challenges that will help companies evaluate and develop growth strategies. Learn More COVID Impact and Recovery Analysis Many elective surgeries, such as the appendix, kidney, and gallbladder stone surgeries were postponed for two to three months in early 2020 to prevent the spread of COVID-19. More than 500,000 surgical procedures were either postponed or canceled in 2020, which led to a decline in the adoption of intravenous fluid bags. However, in 2021, the initiation of large-scale vaccination drives has lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Such factors are expected to drive the market during the forecast period. Related Reports Pressure Infusion Bags Market by Type and Geography - Forecast and Analysis 2022-2026: The pressure infusion bags market share is expected to increase by USD 2.63 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.97%. Find More Exclusive Research Insights Here Medical Specialty Bags Market by Product, End-user, and Geography - Forecast and Analysis 2021-2025: The medical specialty bags market has the potential to grow by USD 5.26 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 5.50%. Find More Exclusive Research Insights Here Table of Contents 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain: Healthcare supplies 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five Forces Analysis Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by End-user 5.1 Market segments 5.2 Comparison by End-user 5.3 Hospitals - Market size and forecast 2020-2025 Exhibit 17: Hospitals - Market size and forecast 2020-2025 ($ million) Exhibit 18: Hospitals - Year-over-year growth 2020-2025 (%) 5.4 Home healthcare - Market size and forecast 2020-2025 Exhibit 19: Home healthcare - Market size and forecast 2020-2025 ($ million) Exhibit 20: Home healthcare - Year-over-year growth 2020-2025 (%) 5.5 Others - Market size and forecast 2020-2025 Exhibit 21: Others - Market size and forecast 2020-2025 ($ million) Exhibit 22: Others - Year-over-year growth 2020-2025 (%) 5.6 Market opportunity by End user Exhibit 23: Market opportunity by End user 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 25: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 26: Geographic comparison 7.3 Asia - Market size and forecast 2020-2025 Exhibit 27: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 28: Asia - Year-over-year growth 2020-2025 (%) 7.4 North America - Market size and forecast 2020-2025 Exhibit 29: North America - Market size and forecast 2020-2025 ($ million) Exhibit 30: North America - Year-over-year growth 2020-2025 (%) 7.5 Europe - Market size and forecast 2020-2025 Exhibit 31: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 32: Europe - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 33: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 34: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 35: Key leading countries 7.8 Market opportunity by geography Exhibit 36: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 37: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Vendor landscape Exhibit 38: Vendor landscape 9.2 Competitive scenario 9.3 Landscape disruption Exhibit 39: Landscape disruption Exhibit 40: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 41: Vendors covered 10.2 Market positioning of vendors Exhibit 42: Market positioning of vendors 10.3 Amcor Plc Exhibit 43: Amcor Plc - Overview Exhibit 44: Amcor Plc - Business segments Exhibit 45: Amcor Ltd. - Key news Exhibit 46: Amcor Plc - Key offerings Exhibit 47: Amcor Plc - Segment focus 10.4 B. Braun Melsungen AG Exhibit 48: B. Braun Melsungen AG - Overview Exhibit 49: B. Braun Melsungen AG - Business segments Exhibit 50: B. Braun Melsungen AG - Key news Exhibit 51: B. Braun Melsungen AG - Key offerings Exhibit 52: B. Braun Melsungen AG - Segment focus 10.5 Baxter International Inc. 10.6 Fresenius Kabi AG Exhibit 58: Fresenius Kabi AG - Overview Exhibit 59: Fresenius Kabi AG - Product and service Exhibit 60: Fresenius Kabi AG - Key news Exhibit 61: Fresenius Kabi AG - Key offerings Exhibit 62: Fresenius Kabi AG - Segment focus 10.7 ICU Medical Inc. Exhibit 63: ICU Medical Inc. - Overview Exhibit 64: ICU Medical Inc. - Business segments Exhibit 65: ICU Medical Inc. - Key news Exhibit 66: ICU Medical Inc. - Key offerings 10.8 JW Lifescience Corp. Exhibit 67: JW Lifescience Corp. - Overview Exhibit 68: JW Lifescience Corp. - Product and service Exhibit 69: JW Lifescience Corp. - Key offerings 10.9 Merit Medical Systems Inc. Exhibit 70: Merit Medical Systems Inc. - Overview Exhibit 71: Merit Medical Systems Inc. - Business segments Exhibit 72: Merit Medical Systems Inc. - Key offerings Exhibit 73: Merit Medical Systems Inc. - Segment focus 10.10 PolyCine GmbH Exhibit 74: PolyCine GmbH - Overview Exhibit 75: PolyCine GmbH - Product and service Exhibit 76: PolyCine GmbH - Key offerings 10.11 Smiths Group Plc Exhibit 77: Smiths Group Plc - Overview Exhibit 78: Smiths Group Plc - Product and service Exhibit 79: Smiths Group Plc - Key offerings 10.12 SSY Group Ltd. Exhibit 80: SSY Group Ltd. - Overview Exhibit 81: SSY Group Ltd. - Business segments Exhibit 82: SSY Group Ltd. - Key news Exhibit 83: SSY Group Ltd. - Key offerings Exhibit 84: SSY Group Ltd. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 85: Currency conversion rates for US$ 11.3 Research methodology Exhibit 86: Research Methodology Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Information sources 11.4 List of abbreviations Exhibit 89: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Vaccine

100 Deals associated with SSY Group Ltd.

100 Translational Medicine associated with SSY Group Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NP-01(Shijiazhuang No. 4 Pharmaceutical Co., Ltd.) ( AXL x VEGFR2 x c-Met )	Advanced Malignant Solid Neoplasm More	Phase 1
SYN045	Pulmonary Arterial Hypertension More	Phase 1
ADN-9	Liver Cirrhosis More	Preclinical
QO-58 ( Kv7.2 x Kv7.3 x Kv7.4 )	Epilepsy More	Preclinical
Ibuprofen ( COX )	Pain More	Suspended

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis